Inhibition of cervical cancer cell growth in vitro and in vivo with dual shRNAs

Gu, Wenyi, Payne, Elizabeth, Sun, Surong, Burgess, Melinda and McMillan, Nigel A. J. (2011) Inhibition of cervical cancer cell growth in vitro and in vivo with dual shRNAs. Cancer Gene Therapy, 18 3: 219-227. doi:10.1038/cgt.2010.72

Attached Files (Some files may be inaccessible until you login with your UQ eSpace credentials)
Name Description MIMEType Size Downloads
UQ230132.pdf Full text (Open Access) application/pdf 245.71KB 103

Author Gu, Wenyi
Payne, Elizabeth
Sun, Surong
Burgess, Melinda
McMillan, Nigel A. J.
Title Inhibition of cervical cancer cell growth in vitro and in vivo with dual shRNAs
Formatted title
Inhibition of cervical cancer cell growth in vitro and in vivo with dual shRNAs
Journal name Cancer Gene Therapy   Check publisher's open access policy
ISSN 0929-1903
Publication date 2011-03
Year available 2010
Sub-type Article (original research)
DOI 10.1038/cgt.2010.72
Open Access Status File (Author Post-print)
Volume 18
Issue 3
Start page 219
End page 227
Total pages 9
Editor Robert E. Sobol
Kevin J. Scanlon
Place of publication London, United Kingdom
Publisher Nature Publishing Group
Collection year 2011
Language eng
Formatted abstract
RNA interference (RNAi)-based gene silencing is widely used in laboratories for gene function studies and also holds a great promise for developing treatments for diseases. However, in vivo delivery of RNAi therapy remains a key issue. Lentiviral vectors have been employed for stable gene transfer and gene therapy and therefore are expected to deliver a stable and durable RNAi therapy. But this does not seem to be true in some disease models. Here, we showed that lentivirus delivered short-hairpin RNA (shRNA) against human papillomavirus (HPV) E6/E7 oncogenes were effective for only 2 weeks in a cervical cancer model. However, using this vector to carry two copies of the same shRNA or two shRNAs targeting at two different but closely related genes (HPV E6 and vascular endothelial growth factor) was more effective at silencing the gene targets and inhibiting cell or even tumor growth than their single shRNA counterparts. The cancer cells treated with dual shRNA were also more sensitive to chemotherapeutic drugs than single shRNA-treated cells. These results suggest that a multi-shRNA strategy may be a more attractive approach for developing an RNAi therapy for this cancer.
Keyword Lentiviral vector
Dual shRNA
Cervical cancer
Q-Index Code C1
Q-Index Status Confirmed Code
Institutional Status UQ
Additional Notes Published online: 19 November 2010.

Document type: Journal Article
Sub-type: Article (original research)
Collections: Official 2011 Collection
UQ Diamantina Institute - Open Access Collection
UQ Diamantina Institute Publications
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 7 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 11 times in Scopus Article | Citations
Google Scholar Search Google Scholar
Created: Thu, 24 Feb 2011, 15:04:22 EST by Kylie Hengst on behalf of UQ Diamantina Institute